Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

NCT03704467 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: M6620
DRUG: Avelumab
DRUG: Carboplatin

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]